Seed funding from the Cancer Research Institute for early-stage, pre-development technologies with the potential to transform cancer immunotherapy. Supports bold, high-risk/high-reward concepts that bridge technology development and clinical cancer immunology.
Eligibility Criteria:
-
Applicant holds a tenure-track position at a not-for-profit research center or institution (U.S. or abroad).
-
Projects should be led by technology developers collaborating with clinical cancer immunologists (co-PIs encouraged).
-
Not intended for incremental improvements or routine application of existing technologies; proposals must feature substantive new instrumentation, devices, platforms, or algorithms.
-
Clinical trials are not supported (use of samples from independently funded trials is allowed for technology development).
Funding Details:
-
Up to USD 600,000 total over 2–4 years.
-
Indirect costs: up to 10% of the total award, provided in addition to awarded funds.
-
Example areas include computational systems biology, advanced molecular profiling, real-time in vivo visualization, complex multicellular culture systems, and novel therapeutic technologies.
Deadline:
-
LOI Deadline: November 15, 2025 (11:59 p.m. Eastern Time).
-
Invited Full Proposal Deadline: March 2, 2026 (observed, as March 1 falls on a weekend).
-
Earliest award start date: July 1 (awards activate on the first of the month).
Where to go for further information: